Granted Patent
B2
US 12,440,473 · App. 17/461,325 · Granted Oct 14, 2025
Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain
Assignee:
Epitracker, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions comprising fatty acid analogs are provided for treating conditions involving impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, and convulsion, and other conditions. Methods for the diagnosis and monitoring of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, addiction, seizure, convulsion, and other conditions are also provided.
Claims (24)
1. A method of treatment of a condition selected from the group consisting of impaired cognition, movement disorders, chronic pain, depression, decreased appetite, convulsion, seizure, anorexia, cachexia, and addiction, comprising:
administering to a patient in need thereof, a pharmaceutical composition comprising an effective amount of a compound having a structure selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the pharmaceutical composition is in a unit dosage form.
3. The method of claim 1 , comprising from 0.01 mg to 10000 mg of the compound of Formula (I), or pharmaceutically acceptable salt thereof.
4. The method of claim 1 , for the treatment of cognitive impairment.
5. The method of claim 4 , wherein the cognitive impairment is Alzheimer's disease.
6. The method of claim 1 , for treatment of a movement disorder.
7. The method of claim 6 , wherein the movement disorder is multiple sclerosis or Parkinson's disease.
8. The method of claim 1 , for treatment of addiction.
9. The method of claim 8 , wherein the addiction is opioid addiction.
10. The method of claim 1 , for treatment of anorexia or cachexia.
11. The method of claim 10 , wherein the condition with anorexia or cachexia is selected from the group consisting of cancer, AIDS, and advanced age.
12. The method of claim 1 , wherein the condition is chronic pain.
13. The method of claim 1 , wherein the condition is depression.
14. The method of claim 1 , wherein the compound of Formula (I) is:
15. The method of claim 14 , for the treatment of chronic pain.
16. The method of claim 14 , for the treatment of depression.
17. The method of claim 1 , wherein the compound of Formula (I) is:
18. The method of claim 17 , for treatment of addiction.
19. The method of claim 1 , wherein the compound of Formula (I) is:
20. The method of claim 19 , for the treatment of depression.
21. The method of claim 1 , wherein the compound of Formula (I) is:
22. The method of claim 21 , for treatment of depression.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 24, 2025
From: VENN-WATSON, STEPHANIE
To: EPITRACKER, INC.
Reel/Frame 073022/0381 →
Continuity (4)
Continuation
PCTUS2020020697
· Mar 2, 2020
Provisional Application
62824247
· Mar 26, 2019
Provisional Application
62813566
· Mar 4, 2019
References Cited (400)
US 4252159A
· Maki
· 1981
[cited by applicant]
US 4718430A
· Holzer
· 1988
[cited by applicant]
US 4985015A
· Obermann et al.
· 1991
[cited by applicant]
US 5318521A
· Slettenmark
· 1994
[cited by applicant]
US 5449688A
· Wahl et al.
· 1995
[cited by applicant]
US 5465728A
· Phillips
· 1995
[cited by applicant]
US 5741816A
· Tsujihara et al.
· 1998
[cited by applicant]
US 6214875B1
· Yang
· 2001
[cited by applicant]
US 6384252B1
· Pageat
· 2002
[cited by applicant]
US 6441036B1
· Berge
· 2002
[cited by applicant]
US 6544541B1
· Zahradka
· 2003
[cited by applicant]
US 7012053B1
· Barnabas et al.
· 2006
[cited by applicant]
US 7375135B2
· Najib-Fruchart et al.
· 2008
[cited by applicant]
US 7651845B2
· Doyle et al.
· 2010
[cited by applicant]
US 8030348B2
· Sampalis
· 2011
[cited by applicant]
US 8088825B2
· Berge et al.
· 2012
[cited by applicant]
US 8106093B2
· Roe
· 2012
[cited by applicant]
US 8251904B2
· Zivitz et al.
· 2012
[cited by applicant]
US 8759558B2
· Holmeide et al.
· 2014
[cited by applicant]
US 8827957B2
· Searle et al.
· 2014
[cited by applicant]
US 9282760B2
· Bryhn et al.
· 2016
[cited by applicant]
US 9295637B2
· Perricone
· 2016
[cited by applicant]
US 9561206B2
· Venn-Watson
· 2017
[cited by applicant]
US 9662306B2
· Venn-Watson
· 2017
[cited by applicant]
US 9687461B2
· Venn-Watson
· 2017
[cited by applicant]
US 9707199B2
· Venn-Watson
· 2017
[cited by applicant]
US 9713600B2
· Venn-Watson
· 2017
[cited by applicant]
US 20020156351A1
· Sagel
· 2002
[cited by applicant]
US 20030203004A1
· Kelm et al.
· 2003
[cited by applicant]
US 20030203042A1
· Cook
· 2003
[cited by applicant]
US 20060154833A1
· Katou et al.
· 2006
[cited by applicant]
US 20060269495A1
· Popp et al.
· 2006
[cited by applicant]
US 20060275294A1
· Omoigui
· 2006
[cited by applicant]
US 20090318369A1
· Paige et al.
· 2009
[cited by applicant]
US 20110098358A1
· Fujimoto et al.
· 2011
[cited by applicant]
US 20110182943A1
· Kanwar et al.
· 2011
[cited by applicant]
US 20110190702A1
· Stumber
· 2011
[cited by applicant]
US 20110201558A1
· Roe et al.
· 2011
[cited by applicant]
US 20120072236A1
· Atkin
· 2012
[cited by applicant]
US 20140303228A1
· Lawton et al.
· 2014
[cited by applicant]
US 20160195558A1
· Venn-Watson et al.
· 2016
[cited by applicant]
US 20190054052A1
· Shchepinov
· 2019
[cited by applicant]
US 20190240181A1
· Venn-Watson
· 2019
[cited by applicant]
US 20210046034A1
· Venn-Watson
· 2021
[cited by applicant]
US 20210346419A1
· Venn-Watson
· 2021
[cited by applicant]
US 20230201153A1
· Venn-Watson
· 2023
[cited by applicant]
US 20230293491A1
· Venn-Watson
· 2023
[cited by applicant]
US 20230381127A1
· Venn-Watson
· 2023
[cited by applicant]
US 20240016773A1
· Venn-Watson
· 2024
[cited by applicant]
US 20240277649A1
· Venn-Watson et al.
· 2024
[cited by applicant]
US 20240307336A1
· Venn-Watson
· 2024
[cited by applicant]
CA 2337484A1
· 2001
[cited by applicant]
CN 1939332A
· 2007
[cited by applicant]
CN 102327368A
· 2012
[cited by applicant]
DE 2615061
· 1977
[cited by applicant]
DE 102010010666A1
· 2011
[cited by applicant]
EP 1000071A1
· 2000
[cited by applicant]
EP 1020179A2
· 2000
[cited by applicant]
EP 3301090A1
· 2018
[cited by applicant]
JP S60172925
· 1985
[cited by applicant]
JP S61015809A
· 1986
[cited by applicant]
JP S62012716
· 1987
[cited by applicant]
JP S63099063
· 1988
[cited by applicant]
JP H06172168A
· 1994
[cited by applicant]
JP 2003160486A
· 2003
[cited by applicant]
JP 2004115438A
· 2004
[cited by applicant]
JP 2005523331A
· 2005
[cited by applicant]
JP 2008255022A
· 2008
[cited by applicant]
JP 2008540393
· 2008
[cited by applicant]
JP 2010260833A
· 2010
[cited by applicant]
JP 2011528350A
· 2011
[cited by applicant]
JP 2014080432A
· 2014
[cited by applicant]
JP 2015010067A
· 2015
[cited by applicant]
JP 2016504403
· 2016
[cited by applicant]
JP 6029668B2
· 2016
[cited by applicant]
JP 2017200910A
· 2017
[cited by applicant]
JP 2017536879A
· 2017
[cited by applicant]
KR 20170087813A
· 2017
[cited by applicant]
KR 201701009096A
· 2017
[cited by applicant]
KR 102087634B1
· 2020
[cited by applicant]
WO WO199626647
· 1996
[cited by applicant]
WO WO199632850
· 1996
[cited by applicant]
WO WO1999001103
· 1999
[cited by applicant]
WO WO1999002485
· 1999
[cited by applicant]
WO WO2000040217
· 2000
[cited by applicant]
WO WO2004057982
· 2004
[cited by applicant]
WO WO2004069240
· 2004
[cited by applicant]
WO WO2005099483
· 2005
[cited by applicant]
WO WO2005120485
· 2005
[cited by applicant]
WO WO2006038063
· 2006
[cited by applicant]
WO WO2006117668
· 2006
[cited by applicant]
WO WO2007002365
· 2007
[cited by applicant]
WO WO2007100435
· 2007
[cited by applicant]
WO WO2008114732
· 2008
[cited by applicant]
WO WO2010123930
· 2010
[cited by applicant]
WO WO2012001336
· 2012
[cited by applicant]
WO WO2012069790
· 2012
[cited by applicant]
WO WO2013007700
· 2013
[cited by applicant]
WO WO2014108573
· 2014
[cited by applicant]
WO WO2014179341
· 2014
[cited by applicant]
WO WO2015110977
· 2015
[cited by applicant]
WO WO20150140545
· 2015
[cited by applicant]
WO WO2015157514
· 2015
[cited by applicant]
WO WO2016111843
· 2016
[cited by applicant]
WO WO2017186928
· 2017
[cited by applicant]
WO WO2018157013
· 2018
[cited by applicant]
WO WO2019212196
· 2019
[cited by applicant]
WO WO2019222254
· 2019
[cited by applicant]
WO WO2019226572
· 2019
[cited by applicant]
WO WO2020146263
· 2020
[cited by applicant]
WO WO2020154173
· 2020
[cited by applicant]
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916 (Year: 2008).
[cited by examiner]
Horig et al. Journal of Translational Medicine 2004, 2(44) (Year: 2004).
[cited by examiner]
(Haast et al. / Prostaglandins, Leukotrienes and Essential Fatty Acids . 2015; 92, 3-14 (Year: 2015).
[cited by examiner]
Contreras et al. (Biomed Res Int. 2014; 2014: 492141). (Year: 2014).
[cited by examiner]
Moon et al. (Metabolism. Sep. 2014; 63(9): 1131-1140). (Year: 2014).
[cited by examiner]
Harbige et al. (British Journal of Nutrition (2007), 98, Suppl. 1, S46-S53). (Year: 2007).
[cited by examiner]
Silva et al. (Front Pharmacol. 2017; 8: 723.). (Year: 2017).
[cited by examiner]
Irmisch et al. (Prostaglandins Leukot Essent Fatty Acids. 2007; 76: 1-7). (Year: 2007).
[cited by examiner]
Cole et al. (Prostaglandins Leukot Essent Fatty Acids. Aug.-Sep. 2009; 81(0): 213-221). (Year: 2009).
[cited by examiner]
Priebe et al. (Alternative and Complementary Therapies 2019 25:1, 56-58). (Year: 2019).
[cited by examiner]
Borodina et al., “The biology of ergothioneine, an antioxidant nutraceutical”. Nutri Res Reviews (2020) 33: 190-217.
[cited by applicant]
Database WPI, “Pentadecanoic acid compound”, Clarivate Analytics, AN: 2017-637713, Clarivate Analytics, dated: Jul. 2017; 2 pages.
[cited by applicant]
Database WPI, “Immunosuppressive agent . . . ”, AN: 1994-238645, Clarivate Analytics, dated: 1994; 2 pages.
[cited by applicant]
Database WPI, “An effective Saururus chinensisrhizome part . . . ”, An: 2012-B90946, Clarivate Analytics, dated: 2012; 2 pages.
[cited by applicant]
Database WPI, “An anti-aging composition . . . ”, AN: 2004-310751, Clarivate Analytics, dated: 2004; 2 pages.
[cited by applicant]
Sotgia et al., “Hercynine content in widely consumed commercial beverages”. LWT Food Science Tech. Dec. 1, 2018;98: 465-469.
[cited by applicant]
Abdullah et al., “Recommended dairy product intake modulates circulating fatty acid profile in healthy adults: a multi-centre cross-over study”, Br J Nutr. 113(3):435-444.
[cited by applicant]
Adams et al., “Hemochronatosis and iron-overload screening in a racially diverse population.” New Engl J Med. 2005, 352(17):1769-1778.
[cited by applicant]
Adams et al., “A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation”, J Hepatol. 2011, 55(2):453-458.
[cited by applicant]
Ahmad et al., “Interaction of Osteopontin with IL-18 in Obese Individuals: Implications for Insulin Resistance”. PLoS One 2013, 8(5):e63944 in 9 pages.
[cited by applicant]
Akbar et al., Alterations in Hepatic FGF21, Co-Regulated Genes, and Upstream Metabolic Genes in Response to Nutrition, Ketosis and Inflammation in Peripartal Holstein Cows, PLoS One 2015, 10(10):e0139963 in 16 pages.
[cited by applicant]
Akhter, J. MD; Asthma-cure, 2017, https://www.scientificamerican.com/article/can-asthma-be-cured-what/ in 7 pages.
[cited by applicant]
Aksenov et al., “Metabolite Content Profiling of Bottlenose Dolphin Exhaled Breath”, Anal Chem 2014, 86(21):10616-10624.
[cited by applicant]
Altamura et al., “Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis.” J Alzheimer's Dis. 2009, 16(4):879-895.
[cited by applicant]
Anderson et al., “Cholesterol and mortality: 30 years of follow-up from the Framingham Study.” JAMA (1987) 257(16):2176-2180.
[cited by applicant]
Angulo et al., “Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease”. Gastroenterology. 2015, 149(2):389-397.
[cited by applicant]
Ballatore et al., “Carboxylic Acid (Bio)Isosteres in Drug Design”. ChemMedChem. 2013, 8(3):385-395.
[cited by applicant]
Barba et al., Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics. J Cell Mol Med. 2008. 12(5a): 1477-1485.
[cited by applicant]
Barcellini et al., “Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia”. Disease Markers (2015) Article ID 635670 in 7 pages.
[cited by applicant]
Barros et al., “Prey and feeding patterns of resident bottlenose dolphins (Tursiops truncatus) in Sarasota Bay, Florida”, J Mammal. 1998, 79:1045-1059.
[cited by applicant]
Bartke et al., “Bioactive sphingolipids: metabolism and function”. J Lipid Res. (2009) 50(Suppl):S91-S96.
[cited by applicant]
Batista et al., “Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding”, PLoS ONE. 2012, 7(5):e33643 in 7 pages.
[cited by applicant]
Beaton et al., “Treatment of Hyperferritinemia”, Ann Hepatol. 2012, 11(3):294-300.
[cited by applicant]
Benatar et al., “The effects of changing dairy intake on trans and saturated fatty acid levels—results from a randomized controlled study”. Nutr J. 2014, 13:32 in 10 pages.
[cited by applicant]
Berens-McCabe et al., “Prey selection in a resident common bottlenose dolphin (Tursiops truncatus) community in Sarasota Bay, Florida”, Marine Biol. 2010, 157:931-942.
[cited by applicant]
Bettcher et al., “MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes”, Alzheimers Dement (Amst). 2016, 3:91-97.
[cited by applicant]
Bhargava et al., “Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation”, JCI Insight. 2017, 2(19): 1-13.
[cited by applicant]
Bogdanov et al., “Metabolomic profiling to develop blood biomarkers for Parkinson's disease”, Brain 2008. 131(2):389-396.
[cited by applicant]
Bossù et al., “Interleukin-18 produced by peripheral blood cells is increased in Alzheimer's disease and correlates with cognitive impairment”. Brain Behav Immun. 2008, 22(4):487-492.
[cited by applicant]
Calder et al., “n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases.” Am J Clin Nutr. 2006, 83(6 suppl):1505S-1519S.
[cited by applicant]
Calder P.C., “Long-chain polyunsaturated fatty acids and inflammation”, Scandinavian J Food Nutr. 2006, 50(S2):54-61.
[cited by applicant]
Camaschella C., “Iron-Deficiency Anemia”, New Engl J Med. (2015) 372(19):1832-1843.
[cited by applicant]
Cater et al., “Behenic acid is a cholesterol-raising saturated fatty acid in humans.” Am J Clin Nutr. 2001, 73(1):41-44.
[cited by applicant]
Cheng et al., “Distinct Metabolomic Signatures Are Associated with Longevity in Humans.”, Nat Commun. 2015, 6:6791 in 22 pages.
[cited by applicant]
Choi et al., “Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study”. Arch Intern Med. 2005, 165(9):997-1003.
[cited by applicant]
Colegrove K., Histomorphology of the bottlenose dolphin (Tursiops truncatus) pancreas and association of increasing islet ß-cell size with chronic hypercholesterolemia. Gen Comp Endocrinol. 2015, 214:17-23.
[cited by applicant]
Collino et al., “Metabolic Signatures of Extreme Longevity in Northern Italian Centenarians Reveal a Complex Remodeling of Lipids, Amino Acids, and Gut Microbiota Metabolism”. PLoS ONE. 2013, 8(3):e56564.
[cited by applicant]
Corso et al., Corso et al., “Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia”, Dement Geriatr Cogn Disord Extra. 2017, 7(1):143-159.
[cited by applicant]
Craik J., GLUT-1 mediation of rapid glucose transport in dolphin (Tursiops truncatus) red blood cells. Am J Physiol. 1998, 274(1 Pt 2):R112-R119.
[cited by applicant]
Croes et al., Formation of a 2-methyl-branched fatty aldehyde during peroxisomal alpha-oxidation. FEBS Lett. 1997, 412(3):643.645.
[cited by applicant]
Cronet et al., “Structure of the PPARα and -γLigand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family”, Structure. 2001, 9(8):699-706.
[cited by applicant]
Cusi et al., “Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial”. Ann Intern Med. 2016, 165(5):305-315.
[cited by applicant]
Daak et al., “Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial”. Am J Clin Nutr. 2013, 97(1):37-44.
[cited by applicant]
DAS Undurti N., “Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review”, J Adv Res. 2018, 11:43-55.
[cited by applicant]
Diehl et al., “Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis”. N Engl J Med. 2017, 377(21):2063-2072.
[cited by applicant]
Di Paolo et al., “Linking Lipids to Alzheimer's Disease: Cholesterol and Beyond”, Nat Rev Neurosci. 2011, 12(5):284-296.
[cited by applicant]
Dongiovanni et al., “Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target”. J Hepatol. 2011, 55:920-932.
[cited by applicant]
Dursun et al., 2015, The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's d…
[cited by applicant]
Durzan D.J., Arginine, scurvy and Cartier's “tree of life”. J Ethnobio Ethnomed. 2009. 5(1): 1-16.
[cited by applicant]
Ekstedt et al., “Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.” Hepatology. 2015; 61(5): 1547-1554.
[cited by applicant]
Ellervik et al., “Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study”, Lancet 2001, 358(9291):1405-1409.
[cited by applicant]
Evans et al., “NAD+ metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity.” BMC Chem Biol. 2010, 10:2 in 10 pages.
[cited by applicant]
Fargion et al., “Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis”. Am J Gastroenterol. 2001, 96(8):2448-2455.
[cited by applicant]
Favé et al., “Physicochemical properties of lipids: new strategies to manage fatty acid bioavailability”. Cell Mol Biol. 2004, 50(7):815-831.
[cited by applicant]
FDA Guidance for Industry. “Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.” U.S. Food and Drug Administration, Jul. 2005 in 30 pages.
[cited by applicant]
FDA (2017) FDA drug safety communication: FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. Accessed Dec. 5, 2017 https://www.fda.gov/Drugs/DrugSafety/ucm576656.htm in …
[cited by applicant]
Fernandes et al., “Relationship between Acute Phase Proteins and Serum Fatty Acid Composition in Morbidly Obese Patients”, Dis Markers 2013, 35(2):104-112.
[cited by applicant]
Forman et al., “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ”, Proc Natl Acad Sci U.S.A., 1997, 94(9):4312-4317.
[cited by applicant]
Forouhi et al., “Differences in the Prospective Association Between Individual Plasma Phospholipid Saturated Fatty Acids and Incident Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study”, Lancet Diabetes Endocrinal, 20…
[cited by applicant]
Fujiwara et al., “Biology of Heme in mammalian Erythroid Cells and Related Disorders”. BioMed Res Int'l. (2015) Article ID 278536 in 9 pages.
[cited by applicant]
Gabrielsen et al., “Adipocyte iron regulates adiponectin and insulin sensitivity”. J Clin Invest. 2012, 122(10):3529-3540.
[cited by applicant]
Ghannadi et al., “An Investigation of the Analgesic and Anti-Inflammatory Effects of Nigella sativa Seed Polyphenols”, J Med Food. 2005, 8(4): 488-493.
[cited by applicant]
Gibson Ra., “Australian fish—An excellent source of both arachidonic acid and ω-3 polyunsaturated fatty acids”, Lipids 1983, 18(11):743-752.
[cited by applicant]
Giunta et al., “Inflammaging as a prodrome to Alzheimer's disease”, J Neuroinflammation 2008, 5:51; 15 pages.
[cited by applicant]
Glauber et al., “Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus”, Ann Intern Med. 1988, 108(5):663-668.
[cited by applicant]
Gonzalez-Covarrubias et al., “Lipidomics of familial longevity”. Aging Cell. 2013, 12(3):426-434.
[cited by applicant]
Gonzalez-Covarrubias V., “Lipidomics in longevity and healthy aging”. Biogerontology. 2013, 14(6):663-672.
[cited by applicant]
Ghosh et al., “PAI-1 in tissue fibrosis.” J Cell Physiol. (2011) 227(2):493-507.
[cited by applicant]
Grundy et al., “Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition”, Circulation. 2004, 109(3):433-…
[cited by applicant]
Gunstone et al. [Eds.], “A review of even-chain fatty acid metabolism and the role of arachidic acid (C20:0) and lignoceric acid (C24:0) in health and disease”, The Lipid Handbook, Gunstone et al. [Eds.] 3rd Edition, 20…
[cited by applicant]
Hallgren et al., “Lymphocyte phytohemagllutinin responsiveness, immunoglobulins and autoantibodies in aging humans.” J Immunol. (1973) 111:1101-1107.
[cited by applicant]
Hall et al., “Annual, seasonal and individual variation in hematology and clinical blood chemistry profiles in bottlenose dolphins (Tursiops truncatus) from Sarasota Bay, Florida”, Comp Biochem Physiol A Mol Integr Phys…
[cited by applicant]
Hannun et al., “Principles of bioactive lipid signalling: lessons from sphingolipids”, Nat Rev Mol Cell Biol. 2008, 9(2):139-150.
[cited by applicant]
Hassanali et al., “Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat”, Diabetes Obes Metab. 2010, 12(2):139-14…
[cited by applicant]
Hebbel et al., A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis, Cardiovsc Hematol Disord Drug Targets (200() 9(4):271-291.
[cited by applicant]
Heneka et al., “Neuroinflammation in Alzheimer's Disease”, Lancet Neurol. 2015, 14(4):388-405.
[cited by applicant]
Hodge et al., “Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: Interpreting the role of linoleic acid.” Am J Clin Nutrition (2007) 86(1): 189-197.
[cited by applicant]
Hodson et al., “Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake”, Prog Lipid Res. 2008, 47:348-380.
[cited by applicant]
Holmes et al., “Systemic inflammation and disease progression in Alzheimer disease”. Neurology 2009, 73(10):768-774.
[cited by applicant]
Hwang et al., “Inhibitory Effects of 4-Guanidinobutyric Acid against Gastric Lesions”, Biomol Ther. 2012, 20(2): 239-244.
[cited by applicant]
International Diabetes Federation (2006) The IDF consensus worldwide definition of the Metabolic Syndrome. Brussels, Belgium., in 24 pages.
[cited by applicant]
Jaruvongvanich et al., “Outcome of phlebotomy for treating nonalcoholic fatty liver disease: a systematic review and meta-analysis”. Sauid J Gastroenterol. 2016, 22(6):407-414.
[cited by applicant]
Jenkins et al., “A Review of Odd-Chain Fatty Acid Metabolism and the Role of Pentadecanoic Acid (C15:0) and Heptadecanoic Acid (C17:0) in Health and Disease”, Molecules (2015) 20(2):2425-2444.
[cited by applicant]
Jeon et al., “S-adenosylhomocysteine treatment of adult female fibroblasts alters X-chromosomeinactivation and improves in vitro embryo development after somatic cell nuclear transfer”, Reproduction, (2008) 135: 815-828.
[cited by applicant]
Johnson et al., “Use of phlebotomy treatment in Atlantic bottlenose dolphins with iron overload”. J Am Vet Med Assoc. 2009, 235(2):194-200.
[cited by applicant]
Jové et al. Metabolomics of human brain aging and age-related neurodegenerative diseases. J Neuropathol Exp Neurol. 2014, 73(7): 640-657.
[cited by applicant]
Kaddurah-Daouk, et al., Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacol 2009. 34(1): 173-186.
[cited by applicant]
Kanda et al., “MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity”, J Clin Invest. 2006, 116(6):1494-1505.
[cited by applicant]
Kersten et al., “Roles of PPARs in health and disease”, Nature. 2000, 405(6785):421-424.
[cited by applicant]
Kiyota et al., “CCL2 Accelerates Microglia-Mediated Aβ Oligomer Formation and Progression of Neurocognitive Dysfunction”. PLoS ONE. 2009, 4:e6197 in 12 pages.
[cited by applicant]
Klock et al., “Sodium ascorbyl phosphate shows in vitro and in vivo efficacy in the prevention and treatment of acne vulgaris”, International Journal of Cosmetic Science, 2005, 27(3):171-176.
[cited by applicant]
Krachler et al., “Fatty Acid Profile of the Erythrocyte Membrane Preceding Development ofType 2 Diabetes Mellitus”, Nutri Metabol Cardiovasc Diseases, (2008) 18(7):503-510.
[cited by applicant]
Kratz et al., The relationship between high-fat dairy consumption and obesity, cardiovascular, and metabolic disease. Eur J Nutr. (2013) 52: 1-24.
[cited by applicant]
Kratz et al., “Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans”, Am J Clin Nutr. 2014, 99(6):1385-1396.
[cited by applicant]
Kriesberg et al., Cholesterol metabolism and aging, Am J Med. (1987) 82: 54-60.
[cited by applicant]
Kristal et al., “Metabolomics: Opening Another Window into Aging”. Sci Aging Knowledge Environ. 2005, 26:pe19 in 2 Pages.
[cited by applicant]
Kühn et al., 2012, “Effect of Multipeak Spectral Modeling of Fat for Liver Iron and Fat Quantification: Correlation of Biopsy with MR Imaging Results”. Radiology. 2012, 265(1):133-142.
[cited by applicant]
LaBrecque et al., “World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis”. J Clin Gastroenterol. 2014, 48(6):467-473.
[cited by applicant]
Lagerstedt et al., “Quantitative determination of plasma c8-c26 total fatty acids for the biochemical diagnosis of nutritional and metabolic disorders”, Mol Genet Metab. 2001, 73(1):38-45.
[cited by applicant]
Lai et al., “The protective effects and genetic pathways of thorn grape seeds oil against high glucose-induced apoptosis in pancreatic beta-cells”, BMC Complement Altern Med. 2014, 14:10 (7 pages).
[cited by applicant]
Lefebvre et al., “Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis”. PLoS ONE. 2016. 11(6):e0158156 in 19 pages.
[cited by applicant]
Leyton et al., “Differential oxidation of saturated and unsaturated fatty acids in vivo in the rat”. Br J Nutr. 1987, 57(3):383-393.
[cited by applicant]
Liao et al., “Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis”. BMJ Open. 2017, 7(1):e013927 in 13 pages.
[cited by applicant]
Liu et al., “Serum biomarkers for nonalcoholic fatty liver disease: Are we there yet?”, Hepatology. 2017, 65(1):8-11.
[cited by applicant]
Livrea et al., “Oxidative stress and antioxidant status in ß-thalassemia major: iron overload and depletion of lipid-soluble antioxidants.” Blood. 1996, 88(9):3608-3614.
[cited by applicant]
Loomba et al., “The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial”. Hepatology. 2018, 67(2):549-559; avail online Dec. 2017; in 11 pages.
[cited by applicant]
Luquet et al., “Roles of PPAR δ in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes”, Biochim Biophys Acta. 2005, 1740:313-317.
[cited by applicant]
Luzia et al., “The influence of season on the lipid profiles of five commercially important species of Brazilian fish”, Food Chem. 2003, 83(1):93-97.
[cited by applicant]
Ma et al., “Organization of the mammalian metabolome according to organ function, lineage specialization, and longevity”. Cell Metab. 2015, 22(2):332-343.
[cited by applicant]
Madsen et al., “Tetradecylthioacetic acid prevents high fat diet induced adposity and insulin resistance”, J Lipid Res. 2002, 43:742-750.
[cited by applicant]
Magnusdottir et al., “Plasma alkylresorcinols C17:0/C21:0 ratio, a biomarker of relative whole-grain rye intake, is associated to insulin sensitivity: a randomized study”, Eur J Clin Nutr. 2014, 68(4):453-458.
[cited by applicant]
Månsson H.L., “Fatty acids in bovine milk fat”. Food Nutr Res. 2008, 52:4 in 3 pages.
[cited by applicant]
Martin-Jiménez et al., Relationship between obesity, Alzheimer's disease, and Parkinson's disease: an astrocentric view. Publ. online Oct. 28, 2016; Mol Neurobiol. 2017, 54(9):7096-7115.
[cited by applicant]
Maruyama et al., “Differences in Serum Phospholipid Fatty Acid Compositions and Estimated Desaturase Activities Between Japanese Men With and Without Metabolic Syndrome”, J Atheroscler Thromb. 2008, 15(6):306-313.
[cited by applicant]
Mayneris-Perxachs et al., “Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease”. Clinical Nutrition. 2013…
[cited by applicant]
Mayo Clinic, Asthma, 2017, https://www.mayoclinic.org/diseases-conditions/asthma/basics/treatment/con-20026992 in 6 pages.
[cited by applicant]
Mayo Clinic, Cholesterolgallstones, 2017, https://www.mayoclinic.org/diseases-conditions/gallstones/diagnosis-treatment/drc-20354220 in 3 pages.
[cited by applicant]
Mazzaro et al., “Iron indices among bottlenose dolphins (Tursiops truncatus)”. Comp Med. 2012, 62(6):508-515.
[cited by applicant]
McGeer et al., “Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years”. J Alzheimers Dis. 2016, 54(3):853-857.
[cited by applicant]
McGowen M., “Dolphin genome provides evidence for adaptive evolution of nervous system genes and a molecular rate slowdown”, Proc Biol Sci. 2012, 279(1743):3643-3651.
[cited by applicant]
McMurchie E.J., “Dietary lipids and the regulation of membrane fluidity and function”. Publisher: Alan R. Liss, Inc.; Physiol Reg Memb Fuid. 1988, 189-237.
[cited by applicant]
Meikle et al., “Plasma Lipid Profiling Shows Similar Associations with Prediabetes and Type 2 Diabetes”. PloS one, 2013, 8(9), e74341; 43 pages.
[cited by applicant]
Mennen et al., “Possible protective effect of bread and dairy products on the risk of the metabolic syndrome”, Nutrition Res. 2000, 20(3):335-347.
[cited by applicant]
Mi, “Myocardial Infarction”, 2017, MedlinePlus Medical Encyclopedia; URL:<https://medlineplus.gov/ency/article/000195.htm> in 7 pages.
[cited by applicant]
Miyake et al., “Maternal consumption of dairy products, calcium, and vitamin D during pregnancy and infantile allergic disorders.” Ann Allergy Asthma Immunol. (2014) 113(1): 82-87. (Abstract p. S224).
[cited by applicant]
Montoliu et al., Serum profiling of healthy aging identifies phosphor- and sphingolipid species as markers of human longevity. Aging (Albany NY). 2014, 6(1):9-25.
[cited by applicant]
Morsy et al., “Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?”, Turk J Gastroenterol. 2016, 27:55-61.
[cited by applicant]
Nanji et al., “Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration.”J Pharmacol Exp Ther. 2001, 299(2):638-644.
[cited by applicant]
Nelson et al., “Relationship between the pattern of hepatic iron deposition and histologic severity in nonalcoholic fatty liver disease”. Hepatology. 2011, 53(2):448-457.
[cited by applicant]
Nestel et al., Specific plasma lipid classes and phospholipid fatty acids indicative of dairy food consumption associate with insulin sensitivity. Am J Clin Nutr., 2014, 99(1):46-53.
[cited by applicant]
Nestel P., “Trans fatty acids: are its cardiovascular risks fully appreciated?”. Clin Ther. 2014, 36(3):315-321.
[cited by applicant]
Neuschwander-Tetri et al., “Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial”. Lancet. 2015, 385(9972):95…
[cited by applicant]
Nilsson S., “Long-term treatment with methenamine hippurate in recurrent urinary tract infection”, Acta Med Scand. (1975) 198(1-2): 81-85.
[cited by applicant]
Novgorodtseva et al., “Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome”. Lipids Health Dis. 2011, 10:82 in 5 pages.
[cited by applicant]
Novgorodtseva et al., “Modification of fatty acids composition in erythrocytes lipids in arterial hypertension associated with dyslipidemia”. Lipids Health Dis. 2011, 10:18 in 5 pages.
[cited by applicant]
Oberley et al., “Laboratory testing for cobalamin deficiency in megaloblastic anemia”. Am J Hematol. (2013) 88(6):522-524.
[cited by applicant]
Ojala et al., “Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients”. Neurobiol Aging. 2009, 30(2):198-209.
[cited by applicant]
Otogawa et al., “Erythrophagocytosis by Liver Macrophages (Kupffer Cells) Promotes Oxidative Stress, Inflammation, and Fibrosis in a Rabbit Model of Steatohepatitis: Implications for the Pathogenesis of Human Nonalcohol…
[cited by applicant]
Özogul et al., Fatty acid profiles and fat contents of commercially important seawater and freshwater fish species of Turkey: A comparative study. Food Chem. 2007, 103:217-223.
[cited by applicant]
Panee J., “Monocyte Chemoattractant Protein 1 (MCP-1) in Obesity and Diabetes”, Cytokine. (2012) 60(1):1-12.
[cited by applicant]
Patel et al., “Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European Prospective Inves…
[cited by applicant]
Penckofer et al., “Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and prooxidants”. J Cardiovasc Nurs. 2002, 16(2):68-85.
[cited by applicant]
Pereira et al., “Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study”, JAMA. 2002, 287(16):2081-2089.
[cited by applicant]
Perry Vh., “Contribution of systemic inflammation to chronic neurodegeneration”. Acta Neuropathol. 2010, 120(3):277-286.
[cited by applicant]
Perry et al., “Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration”. Semin Immunopathol. (2013) 35:601-612.
[cited by applicant]
Pfeuffer et al., “Milk and the metabolic syndrome”, Obes Rev. 2007, 8(2):109-118.
[cited by applicant]
Pfeuffer et al., “Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids”, Adv Nutr. 2016, 7:730-734.
[cited by applicant]
Pietrangelo A. “Iron in NASH, chronic liver diseases and HCC: how much iron is too much?”, J Hepatol. 2009, 50(2):249-251.
[cited by applicant]
Popp-Snijders et al., “Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes”, Diabetes Res 1987, 4(3):141-147.
[cited by applicant]
Profenno et al., “Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders”, Biol Psychiatry. 2010, 67(6):505-512.
[cited by applicant]
Pubchem. Cid 325395, Mar. 26, 2005; pp. 1-13; retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov//compound/325395>.
[cited by applicant]
Qin et al., “Peroxisome proliferator-activated receptor-δ induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice”, Hepatology, 2008, 48(2):432-441.
[cited by applicant]
Ramírez et al., “Absorption and distribution of dietary fatty acids from different sources”. Early Hum Develop. 2001, 65(Suppl):S95-S101.
[cited by applicant]
Ratziu V., “Novel pharmacotherapy options for NASH”. Dig Dis Sci. 2016, 61(5):1398-1405.
[cited by applicant]
Ratziu et al., “Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening”. Gastroenterology. 2016, 150(5):1147-115…
[cited by applicant]
Robinson et al., “N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome.” Lipids. 2013, 48(4):319-332.
[cited by applicant]
Ross et al., “CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study”. Curr Alzheimer Res. 2013, 10(7):742-753.
[cited by applicant]
Ruidavets et al., “High consumptions of grain, fish, dairy products and combinations of these are associated with a low prevalence of metabolic syndrome”, J Epidemiol Community Health, 2007, 61(9):810-817.
[cited by applicant]
Safadi et al., “The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease”. Clin Gastroenterol Hepatol. 2014, 12(12):2085-2091.
[cited by applicant]
Salameh et al., “Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease”, Exp Biol Med (Maywood). 2016, 241(15):1676-1683.
[cited by applicant]
Salek et al., A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int. 2010. 56(8): 937-947.
[cited by applicant]
Sanches et al., “Nonalcoholic Steatohepatitis: A Search for Factual Animal Models”. Biomed Res Int. 2015, doi: [10.1155/2015/574832] in 13 pages.
[cited by applicant]
Sandrou et al., “Low-fat/calorie foods: current state and perspectives”, Crit Rev Food Sci Nutr. 2000, 40(5):427-447.
[cited by applicant]
Sarikurkcu et al., “Screening of Possible in Vitro Neuroprotective, Skin Care, Antihyperglycemic, and Antioxidative Effects of Anchusa undulata L. subsp. hybrida (Ten.) Coutinho from Turkey and Its Fatty Acid Profile”, …
[cited by applicant]
Sarikurkcu et al., Publication date, 2019, email dated Jun. 18, 2019 in 19 pages.
[cited by applicant]
Schmeda-Hirschmann et al., Anti-inflammatory activity of animal oils from the Peruvian Amazon. J Ethnopharmacol. 2014, 156:9-15.
[cited by applicant]
Seki et al., “Eicosapentaenoic Acid (EPA) Attenuates the Anemia Due to Ribavirin/Interferon a Treatment in Patients with Chronic Hapatitis C”, 2004, 3199 in 4 pages.
[cited by applicant]
Shaw C., “Possible Modulation by Glutathione of Glutamatergic”, in Glutathione in the Nervous System, CRC Press, 1998. Chapter 7, pp. 140-142.
[cited by applicant]
Sindhu et al., “Obesity is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous Adipose Tissue: Significance for Metabolic Inflammation”. PLoS ONE. 2015, 10(7):e0133494 in 17 pages.
[cited by applicant]
Slifka Ka. , Comparative diet analysis of fish species commonly consumed by managed and free-ranging bottlenose dolphins (Tursiops truncatus). Int J Vet Med. (2013) 10:1.
[cited by applicant]
Sobolesky et al., “Feeding a Modified Fish Diet to Bottlenose Dolphins Leads to an Increase in Serum Adiponectin and Sphingolipids”, Front Endocrinol. 2016, 7:33 in 11 pages.
[cited by applicant]
Sorrentino et al., “Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis”. J Hepatol. 2009, 50(2):351-357.
[cited by applicant]
Spyridaki et al., (2016) Obesity, inflammation and cognition. Curr Opin Behav Sci. 2016, 9: 169-175.
[cited by applicant]
Stephenson et al., “Building a Roadmap for Developing Combination Therapies for Alzheimer's Disease”, Expert Rev Neurother. 2015, 15(3):327-333.
[cited by applicant]
Suresh et al., “Protective action of arachidonic acid against alloxan-induced cytotoxicity and diabetes mellitus”. Prostaglandins Leukot Essent Fatty Acids, 2001, 64(1):37-52.
[cited by applicant]
Swaminathan et al., “The role of iron in diabetes and its complications”, Diabetes Care. 2007, 30(7):1926-1933.
[cited by applicant]
Targher et al., “Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications”. Diabetes Care (2001) 24(5):956-957.
[cited by applicant]
Targher et al., “Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease”, N Engl J Med., 2010, 363:1341-1350.
[cited by applicant]
Trushina et al., Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS ONE 2013. 8(5): e63644 in 13 pages.
[cited by applicant]
Trushina et al., Recent advances in the application of metabolomics to Alzheimer's disease. Bioch Biophy Acta. 2014.1842(8): 1232-1239.
[cited by applicant]
Tucsek et al., “Obesity in Aging Exacerbates Blood-Brain Barrier Disruption, Neuroinflammation, and Oxidative Stress in the Mouse Hippocampus: Effects on Expression of Genes Involved in Beta-Amyloid Generation and Alzhe…
[cited by applicant]
Unnikrishnan et al., “Antiinflammatory activity of methionine, methionine sulfoxide and methionine sulfone”. Agents Actions. 1990, 31(1-2):110-112.
[cited by applicant]
Valenti et al., “Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study”. Am J Gastroenterol. 2007, 102(6):12…
[cited by applicant]
Valenti et al., “[769] Iron Depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study”, J Hepatol. (Apr. 2007) 46:S28…
[cited by applicant]
Valenti et al., “A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia”. World J Gastroenterol. 2014, 20(11):3002-3010.
[cited by applicant]
Van Eldik et al., The roles of inflammation and immune mechanisms in Alzheimer's disease. Alzheimers Dement (N.Y.), 2016, 2(2):99-109.
[cited by applicant]
Venn-Watson et al., “Big brains and blood glucose: common ground for diabetes mellitus in humans and healthy dolphins”, Comp Med., 2007, 57(4):390-395.
[cited by applicant]
Venn-Watson et al., “Assessment of increased serum aminotransferases in a managed Atlantic bottlenose dolphin (Tursiops truncatus) population”, J Wildlf Dis. 2008, 44(2):318-330.
[cited by applicant]
Venn-Watson et al., “Dolphins as animal models for type 2 diabetes: sustained, post-prandial hyperglycemia and hyperinsulinemia”, Gen Comp Endocrinol. 2011, 170(1):193-199.
[cited by applicant]
Venn-Watson et al., Physiology of aging among healthy, older bottlenose dolphins (Tursiops truncatus): comparisons with aging humans. J Comp Phys B. 2011, 181(15):667-680.
[cited by applicant]
Venn-Watson et al., “Hemochromatosis and fatty liver disease: building evidence for insulin resistance in bottlenose dolphins (Tursiops truncatus).” J Zoo Wildl Med. 2012, 43(3 Suppl):S35-S47.
[cited by applicant]
Venn-Watson et al., “Blood-Based Indicators of Insulin Resistance and Metabolic Syndrome in Bottlenose Dolphins (Tursiops truncatus)”, Front Endocrinol (Lausanne) 2013, 4:136 in 8 pages.
[cited by applicant]
Venn-Watson et al., Associations of ceruloplasmin and haptoglobin with inflammation and glucose in bottlenose dolphins (Tursiops truncatus) J Comp Clin Path. 2014, 23(4):1031-1036.
[cited by applicant]
Venn-Watson S., “Dolphins and Diabetes: Applying One Health for breakthrough discoveries”. Front Endocrinol (Lausanne); 2014, 5:227 in 2 pages.
[cited by applicant]
Venn-Watson et al., “Investigation of Fish-Based Nutrients to Protect Against Metabolic Syndrome in Bottlenose Dolphins (Tursiops Truncatus)”, presentation at International Association for Aquatic Animal Medicine (IAAAM…
[cited by applicant]
Venn-Watson et al., “Adrenal Gland and Lung Lesions in Gulf of Mexico Common Bottlenose Dolphins (Tursiops truncatus) Found Dead following the Deepwater Horizon Oil Spill”. PLoS ONE 2015 10(5):e0126538 in 23 pages.
[cited by applicant]
Venn-Watson et al., “Evaluation of annual survival and mortality rates and longevity of bottlenose dolphins (Tursiops truncatus) at the United States Navy Marine Mammal Program from 2004 through 2013”, J Am Vet Med. 201…
[cited by applicant]
Venn-Watson et al., “Increased Dietary Intake of Saturated Fatty Acid Heptadecanoic Acid (C17:0) Associated with Decreasing Ferritin and Alleviated Metabolic Syndrome in Dolphins”, PLoS ONE, 2016, 10(7):e0132117 in 17 p…
[cited by applicant]
Wang et al., “Obesity modifies the relations between serum markers of dairy fats and inflammation and oxidative stress among adolescents.” Obesity (Silver Spring), 2011, 19(12):2404-2410.
[cited by applicant]
Warensjö et al., “Biomarkers of milk fat and the risk of myocardial infarction in men and women: a prospective, matched case-control study.” Am J Clin Nutr. (2010) 92(1):194-202.
[cited by applicant]
Weiss et al., “Anemia of chronic disease.” New Engl J Med. 2005, 352:1011-1023.
[cited by applicant]
Wells et al., “Bottlenose dolphins as marine ecosystem sentinels: developing a health monitoring system”, EcoHealth 2004, 1:246-254.
[cited by applicant]
Wells et al., “Evaluation of Potential Protective Factors Against Metabolic Syndrome in Bottlenose Dolphins: Feeding and Activity Patterns of Dolphins in Sarasota Bay, Florida”, Front Endocrinol (Lausanne), 2013, 4:139 …
[cited by applicant]
Wlazlo et al., Iron metabolism is associated with adipocyte insulin resistance and plasma adiponectin. Diabetes Care, 2012, 36(2):309-315.
[cited by applicant]
Wu et al., “Alterations of the Neuroinflammatory Markers IL-6 and TRAIL in Alzheimer's Disease”, Dement Geriatr Cogn Dis Extra. 2015, 5(3):424-434.
[cited by applicant]
Xu et al., “Molecular Recognition of Fatty Acids by Peroxisome Proliferator—Activated Receptors”, Mol Cell. 1999, 3:397-403.
[cited by applicant]
Yamano et al., “A long-term high-fat diet changes iron distribution in the body, increasing iron accumulation specifically in the mouse spleen.”. J Nutr Sci Vitaminol. (Tokyo) 2015, 61(1):20-27.
[cited by applicant]
Yin et al., “Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature”. Int'l J Clin Exper Pathol. (2015) 8(6):7588 in 6 …
[cited by applicant]
Zandman-Goddard et al., “Hyperferritinemia in autoimmunity”. IMAJ, 2008, 10: 83-84.
[cited by applicant]
Zandman-Goddard et al., “Ferritin in autoimmune diseases”. Autoimmunity Rev. 2007, 6:457-463.
[cited by applicant]
Zhao et al., Body iron stores and heme-iron intake in relation to type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 2012, 7:e41641.
[cited by applicant]
Adachi et al., “Effect of the glyceride of pentadecanoic acid on energy metabolism in hair follicles”. Int J Cosmetic Sci. Jun. 1993;15(3): 125-131.
[cited by applicant]
Agius et al., “The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective”. Int J Mol Sci. May 3, 2020;21(9): 3240 in 19 pages.
[cited by applicant]
Aglago et al., Association between serum phospholipid fatty acid levels and adiposity in Mexican women. J Lipid Res. Jul. 1, 2017;58(7): 1462-1470.
[cited by applicant]
Ali et al., “Recent advances and limitations of mTOR inhibitors in the treatment of cancer”. Cancer Cell Int. Dec. 2022;22(1): 284 in 16 pages.
[cited by applicant]
Ananthakrishnan et al., Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. Feb. 1, 2009;15(2): 182-189.
[cited by applicant]
Anisimov et al., “Metformin slows down aging and extends life span of female SHR mice”. Cell Cycle Sep. 1, 2008;7(17): 2769-2773.
[cited by applicant]
Bartzokis et al., Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging. Mar. 1, 2007;28(3): 414-423.
[cited by applicant]
Barzilai et al, “Metformin as a tool to target aging”. Cell Metab. Jun. 14, 2016;23(6): 1060-1065.
[cited by applicant]
Baum et al., Drug utilization in the U.S.—1985: Seventh annual review. Rockville, MD: Food and Drug Administration, Center for Drugs and Biologies. Dec. 1986.; TOC in 4 pages.
[cited by applicant]
Beanes et al., Down-regulation of decorin, a transforming growth factor-beta modulator, is associated with scarless fetal wound healing. J Pediatr Surg. Nov. 1, 2001;36(11): 1666-1671.
[cited by applicant]
Berg E.L. Phenotypic chemical biology for predicting safety and efficacy. Drug Disc Today Technol. Mar. 1, 2017;23: 53-60.
[cited by applicant]
Bettcher et al., Increases in pro-inflammatory chemokine, MCP-1, are related to decreases in memory over time. Frontiers in aging neuroscience. Feb. 13, 2019; 11:25.
[cited by applicant]
Bialek et al., “Fatty acid composition and oxidative characteristics of novel edible oils in Poland”. CyTA-Journal of Food. Jan. 2, 2017;15(1): 1-8; (published online Jul. 13, 2016).
[cited by applicant]
Bielec et al., Homologies between human and dolphin chromosomes detected by heterologous chromosome painting. Cytogen Genome Res. 1998;81(1): 18-25.
[cited by applicant]
Biong et al., Intake of milk fat, reflected in adipose tissue fatty acids and risk of myocardial infarction: a case-control study. Eur J Clin Nutr. Feb. 2006;60(2):236-244.
[cited by applicant]
Bishop et al., Heptadecanoic acid is not a key mediator in the prevention of diet-induced hepatic steatosis and insulin resistance in mice. Nutrients Apr. 24, 2023;15(9):2052 in 14 pages.
[cited by applicant]
Blagosklonny M.V., Aging and immortality: Quasi-programmed senescence and its pharmacologic inhibition. Cell cycle. Sep. 15, 2006;5(18): 2087-2102.
[cited by applicant]
Blagosklonny M.V., Rapamycin for longevity: opinion article. Aging Oct. 15, 2019;11(19): 8048-8067.
[cited by applicant]
Blagosklonny M.V., “Cell senescence, rapamycin and hyperfunction theory of aging”. Cell Cycle Jul. 18, 2022;21(14): 1456-1467.
[cited by applicant]
Bridle et al., “Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways”. Transplantation Oct. 2009;15(10): 1315-1324.
[cited by applicant]
Browner et al., “The genetics of human longevity”. Am J Med. Dec. 1, 2004;117(11): 851-860.
[cited by applicant]
Brydges et al., Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain, Behavior, and Immunity. May 1, 2022;102:42-52 (available Aug. 5, 2021).
[cited by applicant]
Budczies et al., “Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue—a GC-TOFMS based metabolomics study”. BMC Genomics Dec. 2012;13(1): 334 in 11 pages.
[cited by applicant]
CAS Database Accession No. 1989:205056; “Relationship between structure and anticonvulsant activities of 2-substituted 3-pyrazolidinones”. DU et al., Jun. 10, 1989; 2 pages.
[cited by applicant]
Chaib et al., “Cellular senescence and senolytics: the path to the clinic”. Nat Med. Aug. 2022;28(8):1556-1568.
[cited by applicant]
Chaudhari et al., Increased mitochondrial fusion allows the survival of older animals in diverse C. elegans longevity pathways. Nat Commun. Aug. 3, 2017;8(1): 182 in 16 pages.
[cited by applicant]
Chebib et al., “Guanidino acids act as p1 GABAC receptor antagonists”. Neurochem Res. Apr. 23, 2009; 34(10): 1704-1711.
[cited by applicant]
Cheng et al., “Metformin's mechanisms in attenuating hallmarks of aging and age-related disease”. Aging Dis. Jul. 7, 2022;13(4):970-986.
[cited by applicant]